Description

CAVISEPT 3% NaCl  MAY BE USEFUL FOR:

– ACUTE INFECTIONS OF THE UPPER RESPIRATORY TRACT: RHINITIS, RHINOPHARYNGITIS, LARYNGITIS

– ACUTE LOWER RESPIRATORY TRACT INFECTIONS: TRACHEITIS, BRONCHIOLITIS, BRONCHOPNEUMONIA

– ALLERGIC DISEASES OF THE RESPIRATORY SYSTEM: ALLERGIC RHINITIS AND BRONCHIAL ASTHMA

– CHRONIC RESPIRATORY TRACT DISEASES: BRONCHECTASIAL DISEASE, MUSCULAR FIBROSIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE

– IMMUNOPROPHYLAXIS AND IMMUNOMODULATION OF THE PATHOLOGY OF THE UPPER AND LOWER RESPIRATORY TRACTS

– HYPERTOPHIA OF ADENOIDS

– POSTOPERATIVE APPLICATION AFTER INTERVENTIONS ON THE NOSE AND SURROUNDING CAVITIES.

– DAILY NASAL HYGIENE, ESPECIALLY IN CASES OF DRYING OF THE NASAL MUCOSA.

Method of administration

For single use only. To be used for inhalation from 0+ years or nasal wash after six months. 2 to 4 ml are inhaled twice a day. of the solution through the nose or mouth using an inhaler and/or intranasal administration. If necessary, the dosage can be increased to 4 vials daily.

Form and appearance

Pack of 18 single-dose vials of 4 ml.

What it is made of?

Sodium chloride: 3g; purified water (enough for the amount): 100 ml; without preservatives.

Instructions for use:

Remove the vial from the package and open it by twisting the tip. Pour the inhalation solution into the inhaler. Use your inhaler according to the manufacturer's instructions provided with the system.

MECHANISM OF ACTION

• Restores cilia function
• Immunomodulatory effect
• Anti-inflammatory action
• Improves penetration of antibiotics
• It ensures the drainage of the bronchial tree
• Bronchial mucosa

EFFECTS

• Natural mucolytic effect
• Acts in the focus of the inflammatory process, providing a physiological anti-edematous effect by the mechanism of osmosis
• The effect occurs immediately during inhalation
• It has an additional antibacterial and immodulating effect
• Safe for children (0+), pregnant women, nursing mothers and adults
• Contains no preservatives

CLINICAL STUDIES ON 3% HYPERTONIC SOLUTION 

• Zhang L. et.al. Nebulized hypertonic saline solution for acute bronchiolitis in infants

Cochrane Database Syst Rev. 2008 Oct 8;(4):CD006458

• Mandelberg et.al. Nebulized 3% Hypertonic Saline Solution Treatment in Hospitalized Infants With Viral Bronchiolitis

Chest 2003;123;481-487

• Sarrell EM et.al. Nebulized 3% hypertonic saline solution treatment in ambulatory children with viral bronchiolitis decreases symptoms

Chest, 2002 Dec; 122(6):2015-20

• Sauvaget E. et.al. Nebulized hypertonic saline and acute viral bronchiolitis in infants: current aspects

Arch Pediatr 2012 Jun;19(6):635-41. Epub 2012 Apr 30

• Nagakumar P. et.al. Current therapy for bronchiolitis

Arch Dis Child 2012 Sep;97(9): 827-30. Doi: 10.1136/archdischild-2011-301579. Epub 2012 Jun 25

• Grewal S et.al. A randomized trial of nebulized 3% hypertonic saline with epinephrine in the treatment of acute bronchiolitis in the emergency department

Arch Pediatr Adolesc Med 2009 Nov; 163(11):1007-12. Doi: 10.1001/archpediatrics.2009.196.

• Tal G et.al. Hypertonic saline/epinephrine treatment in hospitalized infants with viral bronchiolitis reduces hospitalization stay: 2 years experience

Isr Med Assoc J. 2006 Mar;8

Additional information

Weight	23 kg
Dimensions	12 × 24 × 35 cm